T5.12 Kilder

Cannabis og psykose

Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011; 342: d738. doi: 10.1136/bmj.d738.

Feiring E. Hasj kan gi psykoser. TnLF 2005; 125: 10.

Bretteville-Jensen AL (red). Hva vet vi om cannabis? Universitetsforlaget 2012, Oslo

Andréasson S1, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987 Dec 26; 2(8574): 1483-6.

Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ : British Medical Journal 2002; 325(7374): 1212-1213.

Gage SH, Hickman M, Zammit S. Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biol Psychiatry 2015 Aug 12. pii: S0006-3223(15)00647-2. doi: 10.1016/j.biopsych.2015.08.001.

Nesvåg R, Reichborn-Kjennerud T, Gillespie NA, Knudsen GP, Bramness JG, Kendler KS, Ystrom E. Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins. Schizophrenia Bulletin, Volume 43, Issue 3, 1 May 2017, Pages 644–653, https://doi.org/10.1093/schbul/sbw101

Cannabismisbruk mulig årsak til psykose. FHI 02.11.2016.

Delirium

Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet 2014; 383; 911.

Barr J, Fraser GL, Puntillo K et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013; 41(1): 263-306.

Overschott R, Karim S, Burns A. Cholinesterase inhibitors for delirium. Cochrane Database Syst Rev 2008; CD005317

Hirota T, Kishi T. Prophylactic antipsychotic use for postoperative delirium: a systematic review and meta-analysis. J Clin Psychiatry 2013; 74: e1136.

Flaherty JH, Gonzales JP, Dong B. Antipsychotics in the treatment of delirium in older hospitalized adults: a systemativ review. J Am Ger Soc 2011; 59 Suppl 2: S269

Campbell N, Boustani MA, Ayub A et al. Pharmacological management in hospitalized adults - a systematic evidence review. J Gen Intern Med 2009; 24: 848.

Serafim RB, Bozza FA, Soares M, et al. Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review. J Crit Care [print-electronic]. 2015 Aug; 30(4): 799-807. PMID: 25957498, PII: S0883-9441(15)00150-1, DOI: 10.1016/j.jcrc.2015.04.005, ISSN: 1557-8615.

Demens

Ossenkoppele R, Jansen WJ, Rabinovici GD et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015 May 19; 313(19): 1939-49.

Gray SL et. al.. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015 Mar; 175(3): 401-7. doi: 10.1001/jamainternmed.2014.7663. http://www.ncbi.nlm.nih.gov/pubmed/25621434

McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No.: CD003160. DOI: 10.1002/14651858.CD003160.pub3.

Depresjoner

Goodwin&Jamison. Manic Depressive Illness, Second Edition, Oxford 2007

Westergren T, Narum S, Klemp M. Critical appraisal of adverse effects reporting in the ‘Treatment for Adolescents With Depression Study (TADS)’. BMJ Open 2019;9:e026089. doi:10.1136/ bmjopen-2018-026089

Hyperkinetiske forstyrrelser

National Institute for Health and Clinical Excellence – ADHD, oppdatert September 2008. http://guidance.nice.org.uk/CG72. Hele «guideline»: http://www.nice.org.uk/nicemedia/pdf/CG072NiceGuidelineV2.pdf.

Bolea-Alamanac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorders: Update on recommendations from the British Association for Psychopharmacology. J Psychopharm 2014; 28(3): 179-203.

ADHD/hyperkinetisk forstyrrelse – nasjonal faglig retningslinje for utredning, behandling og oppfølging Rett diagnose – individuell behandling. Helsedirektoratet Desember 2014 Bestillingsnummer: IS-2060 ISBN-nr. 978-82-8081-283-4

Technology Appraisal 98. Methylphenidate, atomoxetine and dexamfetamine for attention og deficit hyperactivity disorder (ADHD) in children and adolescents (review) http://www.nice.org.uk/nicemedia/pdf/TA098guidance.pdf.

American Academy of Pediatrics, Clinical Practice Guideline: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder: http://www.aappolicy.aappublications.org/cgi/reprint/pediatrics; 108/4/1033.pdf.

Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 2006; 27(1): 1-10.

Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115(6): e749-e757.

Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez A. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry 1993; 32(2): 350-353.

«Behandling med sentralstimulerende legemidler av ADHD hos voksne», notat fra Nasjonalt kunnskapssenter for helsetjenesten (ISBN 82-8121-039-7), Oslo, mars 2005.

Goez HR, Scott O, Nevo N, Bennett-Back O, Zelnik N. Using the Test of Variables of Attention to Determine the Effectiveness of Modafinil in Children With Attention-Deficit Hyperactivity Disorder (ADHD): A Prospective Methylphenidate-Controlled Trial. Journal of Child Neurology 2012; 27(12): 1547 - 52. doi: 10.1177/0883073812439101

Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(1): 145-9.

Seixas M, Weiss M, Müller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol. 2012; 26(6): 753-65.

Childress AC, Sallee FR. Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder. Drugs Today (Barc). 2012; 48(3): 207-17.

Getahun D, et. al. In utero exposure to ischemic-hypoxic conditions and attention-deficit/hyperactivity disorder. Pediatrics 2013; 131(1): 53-61. DOI: 10.1542/peds.2012-1298.

Tourettes syndrom

Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 2011; 20(4): 173-96.

Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry 2012; 57(3): 133-43.

Campbell M, Cueva JE. Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I [Review]. Journal of the American Academy of Child & Adolescent Psychiatry 1995; 34(9): 1124-32.

Scahill L, Erenberg G, Berlin CM, Jr., Budman C, Coffey BJ, Jankovic J et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006; 3(2): 192-206.

Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez A. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry 1993; 32(2): 350-3.

Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J. Clin Psychiatry 2001; 62(1): 50-6.

Budman C, Coffey BJ, Shechter R, Schrock M, Wieland N, Spirgel A et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008; 18(5): 509-15.

Srour M, Lespérance P, Richer F, Chouinard S. Psychopharmacology of tic disorders. J Can Acad Child Adolesc Psychiatry 2008; 17(3): 150-9.

Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010; 81(1): 70-3.

Martínez-Granero MA, García-Pérez A, Montañes F. Levetiracetam as an alternative therapy for Tourette syndrome. Neuropsychiatr Dis Treat. 2010; 6: 309-16.